Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Down 14.2% in January

Spero Therapeutics, Inc. (NASDAQ:SPRO) was the target of a large decrease in short interest during the month of January. As of January 15th, there was short interest totalling 354,100 shares, a decrease of 14.2% from the December 31st total of 412,600 shares. Based on an average trading volume of 301,300 shares, the short-interest ratio is currently 1.2 days.

Spero Therapeutics Stock Performance

Shares of SPRO stock opened at $0.86 on Monday. Spero Therapeutics has a 52-week low of $0.83 and a 52-week high of $1.89. The stock has a market cap of $46.70 million, a price-to-earnings ratio of 12.24 and a beta of 0.61. The firm has a fifty day moving average of $1.01 and a 200-day moving average of $1.20.

Analyst Ratings Changes

Several research analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a research report on Thursday. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a research note on Friday, December 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th.

Institutional Investors Weigh In On Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC lifted its position in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 975,952 shares of the company’s stock after purchasing an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned 1.81% of Spero Therapeutics worth $1,269,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.